← Back to Search

Protein Synthesis Inhibitor

Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma

Phase 2
Waitlist Available
Research Sponsored by Aadi, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 and 12 months
Awards & highlights
No Placebo-Only Group

Summary

This trial tests nab-Sirolimus, a drug for treating difficult brain tumors. It targets patients with specific types of aggressive brain tumors. The drug works by blocking pathways that help tumors grow.

Eligible Conditions
  • Brain Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 and 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
ORR
Secondary study objectives
Median PFS
OS
OS at 12 Months
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

6Treatment groups
Experimental Treatment
Group I: Arm B: nab-sirolimus + temozolomide + radiotherapy in patients with newly diagnosed glioblastomaExperimental Treatment1 Intervention
Induction Treatment (4 weeks) with nab-sirolimus (60 mg/m2 IV weekly); followed by Concomitant Treatment (standard of care; 2 cycles): nab-sirolimus (60 mg/m2 IV on Days 8 and 15 of every 21-day cycle) in combination with TMZ (75 mg/m2 PO daily for 6 weeks) + radiotherapy (30 × 200 cGy, 5 days/week); followed by Adjuvant Treatment (6 cycles) starting 4 weeks after Concomitant Treatment, with nab-sirolimus(60 mg/m2 IV on Days 1, 8, and 15 of every 28-day cycle) in combination with TMZ (150 mg/m2 PO daily on Days 1-5 of every 28-day cycle)
Group II: Arm A, Cohort 5: nab-sirolimus + marizomib (MRZ) in patients with recurrent high grade gliomaExperimental Treatment1 Intervention
nab-Sirolimus was administered at 60 mg/m 2 as a 30-minute IV infusion on Days 1, 8, and 15 of every 28-day cycle. MRZ was administered at 0.8 mg/m 2 as a 10-minute IV infusion on Days 1, 8, and 15 of every 28-day cycle. MRZ was administered approximately 10 minutes after the end of the nab-sirolimus infusion.
Group III: Arm A, Cohort 4: nab-sirolimus + lomustine (CCNU) in patients with recurrent high grade gliomaExperimental Treatment1 Intervention
nab-Sirolimus was administered at 60 mg/m 2 as a 30-minute IV infusion on Days 1 and 8 of every 21-day cycle. CCNU was administered PO at 90 mg/m2 on Day 1 of each odd 21-day cycle (ie, every 6 weeks).
Group IV: Arm A, Cohort 3: nab-sirolimus + bevacizumab in patients with recurrent high grade gliomaExperimental Treatment1 Intervention
nab-Sirolimus (IV 60 mg/m 2 as a 30-minute infusion on Days 1, 8, and 15 of every 28-day cycle). Bevacizumab (IV at a fixed dose of 5 mg/kg on Days 1 and 15 of every 28-day cycle).
Group V: Arm A, Cohort 2: nab-sirolimus + temozolomide (TMZ) in patients with recurrent high grade gliomaExperimental Treatment1 Intervention
nab-Sirolimus (60 mg/m 2 as a 30-minute IV infusion on Days 1, 8, and 15 of every 28-day cycle). Temozolomide (PO at 50 mg/m2 daily)
Group VI: Arm A, Cohort 1: nab-sirolimus in patients with recurrent high grade gliomaExperimental Treatment1 Intervention
nab-Sirolimus (ABI-009, nab-rapamycin, albumin-bound rapamycin) was administered at 100 mg/m2 as a 30-minute IV infusion on Days 1 and 8 of every 21-day cycle.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
nab-sirolimus
2017
Completed Phase 2
~140
nab-sirolimus + temozolomide
2018
Completed Phase 2
~70
nab-sirolimus + bevacizumab
2018
Completed Phase 2
~70
nab-sirolimus + lomustine
2018
Completed Phase 2
~70
nab-sirolimus + marizomib (MRZ)
2018
Completed Phase 2
~70
nab-sirolimus + temozolomide + radiotherapy
2018
Completed Phase 2
~70

Find a Location

Who is running the clinical trial?

Aadi, LLCLead Sponsor
7 Previous Clinical Trials
250 Total Patients Enrolled
Aadi Bioscience, Inc.Lead Sponsor
17 Previous Clinical Trials
516 Total Patients Enrolled
~8 spots leftby Dec 2025